This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports second-quarter earnings.
What Lies Ahead for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of new drug sales. However, the impact of coronavirus pandemic remains to be seen.
3 Strong Dividend Stocks to Buy Now for Income & Coronavirus Growth
by Benjamin Rains
Let's dive into three stocks that are projected to grow during the pandemic that also provide solid income through dividends...
Will Pfizer's (PFE) BioPharma Unit Drive Its Q2 Earnings?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the second quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.
Exelixis Starts Study on Cabometyx Combo in Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche's Tecentriq.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $79.41, marking a -0.58% move from the previous day.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation
by Zacks Equity Research
Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.
Merck's NDA for Heart Failure Candidate Gets Priority Review
by Zacks Equity Research
FDA decision on Merck (MRK) and its Germany-based partner Bayer's vericiguat as a treatment to reduce heart failure is expected in January 2021.
AstraZeneca's Farxiga Gets Fast Track Tag for New Indication
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga gets Fast Track status to reduce the risk of cardiovascular death or hospitalization for heart failure following a heart attack in adult patients.
Pharma Stock Roundup: J&J Q2 Earnings, FDA Approvals, Fast Track Tags & More
by Kinjel Shah
J&J (JNJ) beats Q2 estimates for earnings and sales. FDA grants fast track designation to Pfizer's (PFE) coronavirus vaccine candidates.
What To Expect From The Crazy Earnings Season Ahead
by Daniel Laboe
Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?
Nabriva Soars on Agreement With Merck to Distribute Sivextro
by Zacks Equity Research
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
J&J (JNJ) Beats on Q2 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
J&J (JNJ) beats second-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.
Immunomedics Extends Deal With Roche for Two New Studies
by Zacks Equity Research
Immunomedics (IMMU) extends agreement with Roche to evaluate the combination of Trodelvy and Tecentriq in patients with mUC and mNSCLC.
The Zacks Analyst Blog Highlights: Alphabet, Merck, Medtronic, Netflix and Anheuser-Busch InBev
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Merck, Medtronic, Netflix and Anheuser-Busch InBev
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $77.35, moving +0.81% from the previous trading session.
Roche's (RHHBY) Tecentriq Disappoints in Ovarian Cancer Study
by Zacks Equity Research
Roche's (RHHBY) phase III study on Tecentriq in combination with Avastin fails to meet its primary goal.
Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio
by Zacks Equity Research
Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.
Top Stock Reports for Alphabet, Merck & Medtronic
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Merck (MRK) and Medtronic (MDT).
Merck's Keytruda Gets Priority Review for Lymphoma Indication
by Zacks Equity Research
FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.
Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal
by Kinjel Shah
Merck (MRK) and AstraZeneca (AZN) provide updates on regulatory applications related to key drugs
Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer
by Zacks Equity Research
FDA issues complete response letter to Merck (MRK) and Eisai's applications seeking approval of Keytruda+Lenvima for first-line HCC.
AstraZeneca's Lynparza Gets EU Nod for Pancreatic Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza gets approval in the EU for treating patients with germline BRCA-mutated metastatic pancreatic cancer.